Two features of breast cancer—tumor-infiltrating lymphocytes and tumor budding—might help predict outcomes and guide treatment, according to a recent study published in the journal Cureus.
Tumor-infiltrating lymphocytes are immune cells that enter the tumor and help the body fight it. Tumor budding happens when small groups of cancer cells start to break away from the main tumor and invade nearby tissue.
The study found that tumors with more tumor-infiltrating lymphocytes tended to have less aggressive features, while tumors with more tumor budding showed signs of being more aggressive, such as larger size, higher grade and spread to lymph nodes.
“The observed inverse correlation between tumor-infiltrating lymphocytes and tumor budding suggests a possible interplay between immune-mediated tumor suppression and tumor progression,” the researchers said.
The findings of this study match what other research has shown. Tumor budding has been well documented as a sign of more aggressive cancer, especially in colorectal cancer. Tumor-infiltrating lymphocytes are considered useful for predicting how a cancer might respond to treatment, particularly to chemotherapy and immunotherapy.
Learn more about breast cancer treatment and care
In this study, researchers looked back at 90 cases of invasive breast carcinoma of no special type (IBC-NST), a common type of breast cancer worldwide.
They measured tumor-infiltrating lymphocytes in the tissue around the tumor and inside the tumor itself, and also counted tumor buds at the edge of each tumor.
They found that tumors with more tumor-infiltrating lymphocytes were smaller, lower grade, and had slower growth, while tumors with more tumor budding were larger, higher grade, and more likely to involve lymph nodes or blood vessels.
While these findings show that tumor-infiltrating lymphocytes and tumor budding can give doctors valuable information about a patient’s cancer and help guide personalized treatment, the study did not include information about patient survival.
The study researchers stated larger studies that follow patients over time are needed to confirm how useful these markers are in predicting outcomes and guiding care.